Here is an article of interest that describes progress being made in the treatment of COVID-19 patients. Measurements of progress are difficult but SOC, whether that is defined as use of specific drugs at different stages of illness progression or general hospital treatment activities and best-practice, is evolving and improving. What is absent from care options is a proven antiviral. If Brilacidin proves to be an effective antiviral in clinical trials the demand for its use will be significant.

https://www.statnews.com/2020/11/23/hospitali...ack-gains/